Key facts
- This page summarizes Edward M. Liddy's Form 4 filing for AbbVie Inc. (ABBV).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Apr 2022, 17:16.
Edward M. Liddy - 31 Mar 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)
- Reporting relationship
- Director
- Issuer ticker
- ABBV
- Reported as of
- 31 Mar 2022
- Net transaction value
- +$28,693
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2022, 17:16:25 UTC
- Prior SEC filing
- 04 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- Steven L. Scrogham, attorney-in-fact for Edward M. Liddy
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Edward M. Liddy filed Form 4 for AbbVie Inc. (ABBV) on 04 Apr 2022.
Change
- Previous filing in this sequence was filed on 04 Jan 2022.
- Current net transaction value: +$28,693.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABBV
transaction
Derivative
Stock Equivalent Units
Award
- Transaction value
- $28,693
- Shares
- +177
- Change %
- +0.63%
- Price
- $162.11
- Shares after
- 28,474
- Date
- 31 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 177
- Exercise price
- $162.11
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
Footnote F2
Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.